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ABSTRACT
This study explored the associations between common PSCA single-nucleotide 
polymorphisms (rs2294008, rs2978974, and rs2976392) and breast cancer among 
560 breast cancer cases and 583 controls (Chinese Han women). We found rs2294008 
was significantly associated with a high risk of breast cancer (homozygote model, 
odds ratio [OR]: 1.67, 95% confidence interval [CI]: 1.06–2.59; recessive, OR: 1.64, 
95% CI: 1.06–2.53). And stratification by menopausal status revealed an association 
of the minor allele of rs2294008 with breast cancer risk among premenopausal 
(homozygote model, OR: 2.41, 95% CI: 1.03–5.66; recessive, OR: 2.80, 95 % 
CI: 1.21–6.47) and postmenopausal women (allele model, OR: 1.29, 95% CI: 
1.01–1.65). Rs2978974 influenced the breast cancer risk among postmenopausal 
women in heterozygote model (OR: 1.47, 95% CI: 1.05–2.07). When stratified by 
clinicopathologic features, the T allele of rs2294008 was associated with progesterone 
receptor status (homozygote model, OR: 1.98, 95% CI: 1.08–3.63; recessive, OR: 
1.87, 95% CI: 1.04–3.37), and the rs2976392 polymorphism was associated with 
high lymph node metastasis risk in homozygote model (OR: 2.09, 95%CI: 1.01–
4.31). Further haplotype analysis suggested that Trs2294008 Ars2976392 Grs2978974 haplotype 
enhances breast cancer risk (OR:1.52, 95%CI:1.23-1.89, P<0.001). Therefore, among 
Chinese Han women, the PSCA rs2294008, rs2978974, and rs2976392 minor alleles 
are associated with increased breast cancer risk especially in progesterone receptor 
positive breast cancer patients, with breast cancer risk in postmenopausal women, 
and with high lymph node metastasis risk, respectively. Moreover, Trs2294008 Ars2976392 
Grs2978974 haplotype was associated with significantly increased risk of breast cancer.
INTRODUCTION
Breast cancer is the most common cancer and the 
principal cause of cancer-related deaths among Chinese 
women [1], accounted for 248,620 new cases and 60,473 
cancer-related deaths during 2011 [2]. It is a multi-
factorial disease influenced by complex interactions 
between genetic, environmental, and lifestyle factors [3]. 
Genetic research provides insight into carcinogenesis, 
including the development and treatment of breast cancer. 
Single-nucleotide polymorphisms (SNPs) are variations 
in a single base pair in the DNA sequence and have 
been widely studied in cancer research in recent years. 
Several genes that affect breast cancer risk, including 
BRCA1 (breast cancer 1), BRCA2 (breast cancer 2), PTEN 
(phosphatase and tensin homolog deleted on chromosome 
ten), and TP53 (tumor protein p53) have been identified 
[4–8].
PSCA encodes a 123-amino acid immature lymphocyte 
cell surface maker with 30% homology to stem cell antigen 
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type 2, a member of the Thy-1/Ly-6 family and is located 
on chromosome 8q24.2 [10]. PSCA was initially identified 
as a prostate-specific antigen over-expressed in >80% of 
prostate cancers, including metastatic and hormone-related 
cancers [10, 11]. Recent studies have shown that PSCA is 
also abnormally expressed in bladder cancer [12–14], gastric 
cancer [15–17], renal cell carcinoma [18], oesophageal 
cancer [19], gallbladder cancer [20–22], and pancreatic 
cancer [23]. Studies in vitro indicated that PSCA being 
transfected into PSCA-negative cells caused down-regulated 
cell proliferation, thus affecting survival of gastric cancer 
cells [24]. And, down-regulation of PSCA in a human 
bladder cancer cell line led to inhibition of cell growth via 
activation of several immune signaling pathways [25]. 
Genome-wide association studies have revealed many PSCA 
polymorphisms, among which rs2294008 C>T, rs2978974 
G>A, and rs2976392 G>A are the most widely studied ones 
and may influence susceptibility to different types of cancer 
[22, 26, 27]. However, few studies have been performed to 
investigate the associations of these three PSCA SNPs with 
breast cancer. A single study with small sample sizes (456 
patients and 461controls) revealed that the PSCA SNPs 
were associated with breast cancer susceptibility among 
Korean women [9]. Therefore, the present study aimed to 
comprehensively examine the potential association of three 
SNPs (rs2294008 C>T, rs2978974 G>A, and rs2976392 
G>A) in PSCA with the risk of breast cancer among a 
population of Chinese women.
RESULTS
Associations between PSCA SNPs and the risk of 
breast cancer
Detailed allele frequencies and genotype 
distributions of the three polymorphisms are shown in 
Table 1. The distributions of rs2294008, rs2978974, and 
rs2976392 in the control group were in accordance with 
Hardy-Weinberg equilibrium (P = 0.195, P = 0.164, and P 
= 0.179, respectively). Both the homozygote and recessive 
models of rs2294008 revealed an associated with a high 
risk of breast cancer (TT vs. CC, odds ratio [OR]: 1.67, 
95% confidence interval [CI]: 1.06–2.59, P = 0.03; TT 
vs. CC+TC, OR: 1.64, 95% CI: 1.06–2.53, P = 0.02). 
We further calculated the power of the rs2294008 SNP 
homozygote and recessive model analyses, and we were 
able to reject the null hypothesis that the TT frequency 
for case and controls is equal with probability (power) 
= 0.896. No significant associations with rs2976392 and 
rs2978974 were found in any of the models.
Subgroup analyses according to age and 
menopausal status
Stratification analyses according to age revealed 
no significant associations between the three PSCA SNPs 
and the risk of breast cancer (all, P > 0.05) (Table 2). 
While, stratification analyses according to menopausal 
status (Table 3) found that the minor allele of rs2294008 
was a risk factor among both premenopausal women 
(homozygote model, OR: 2.41, 95% CI: 1.03–5.66, 
P = 0.04; recessive model, OR: 2.80, 95% CI: 1.21–6.47, 
P = 0.01) and postmenopausal women (allele model: OR: 
1.29, 95% CI: 1.01–1.65, P = 0.04). For rs2978974, a 
significant association with high breast cancer risk was 
found among postmenopausal women in the heterozygote 
model (OR: 1.47, 95% CI: 1.05–2.07, P = 0.03). There 
were no significant associations with rs2976392 in any of 
the subgroups.
Associations between PSCA SNPs and the 
clinicopathological features of breast cancer
We evaluated the associations of PSCA SNPs with 
various clinicopathological features including: tumor 
size, lymph node metastasis, and the expressions of 
estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER-2). The 
T allele of rs2294008 was associated with positive PR 
status (homozygote model, OR: 1.98, 95% CI: 1.08–3.63, 
P = 0.03; recessive model, OR: 1.87, 95% CI: 1.04–3.37, 
P = 0.03) (Table 4). The minor allele of rs2976392 was 
associated with a high risk of lymph node metastasis in 
the homozygote model (OR: 2.09, 95% CI: 1.01–4.31, 
P = 0.04). However, rs2978974 was not significantly 
associated with any of the clinicopathological features.
Association between PSCA haplotypes and 
breast cancer risk
We analyzed the association between PSCA 
haplotypes and the risk of breast cancer. Table 5 shows that 
Trs2294008 Ars2976392 Grs2978974 haplotype was associated with 
a significantly increased risk of breast cancer (OR: 1.52, 
95%CI: 1.23–1.89, P<0.001 ). The “others” (haplotypes 
with frequency <1% were merged) were broadly 
distributed in cases at a low level (OR: 0.46, 95%CI: 0.29-
0.71, P<0.001). The significance of this result is limited 
given the naturally low frequencies of these haplotypes. 
We did not discover any associations with Crs2294008 Grs2976392 
Ars2978974 and Trs2294008 Ars2976392 Ars2978974 in breast cancer.
DISCUSSION
Genetic studies have provided insight into 
various diseases, including cancers. Understanding the 
associations between different genes and cancers can 
improve prevention, treatment, and prognosis estimation. 
Genome-wide association studies have revealed many 
genetic markers of different cancers. Recently numerous 
studies have indicated that PSCA may influence a diverse 
group of cancers, including gastric, bladder, renal, and 
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Table 1: Genotype frequencies of PSCA polymorphisms in cases and controls
Model Genotype Cases (n,%) Control (n,%) P† OR (95% CI)
rs2294008 HWE: P=0.195
Co-dominant CC 273 (48.8%) 299 (51.3%)
Heterozygote TC 231 (41.3%) 247 (42.4%) 0.85 1.02 (0.80-1.31)
Homozygote TT 56 (10.0%) 37 (6.3%) 0.03 1.67 (1.06-2.59)
Dominant CC 273 (48.8%) 299 (51.3%)
TC+TT 287 (51.3%) 284 (48.7%) 0.39 1.11 (0.88-1.40)
Recessive CC+TC 504 (90.0%) 546 (93.7%)
TT 56 (10.0%) 37 (6.3%) 0.02 1.64 (1.06-2.53)
Overdominant CC+TT 329 (%) 336 (57.6%)
TC 231 (%) 247 (42.4%) 0.70 0.96 (0.76-1.21)
Allele C 777(69.4%) 845 (72.5%)
T 343(30.6%) 321 (27.5%) 0.10 1.16 (0.97-1.39)
rs2976392 HWE: P=0.164
Co-dominant GG 287 (51.3%) 298 (51.1%)
Heterozygote GA 230 (41.1%) 247 (42.4%) 0.79 0.97 (0.76-1.23)
Homozygote AA 43 (7.7%) 38 (6.5%) 0.50 1.18 (0.74-1.87)
Dominant GG 287 (51.3%) 298 (51.1%)
GA+AA 273 (48.8%) 285 (48.9%) 0.96 1.00 (0.79-1.25)
Recessive GG+GA 517 (92.3%) 545 (93.5%)
AA 43 (7.7%) 38 (6.5%) 0.45 1.19 (0.76-1.88)
Overdominant GG+AA 330 (58.9%) 336 (57.6%)
GA 230 (41.1%) 247 (42.4%) 0.66 0.95 (0.75-1.20)
Allele G 804 (71.8%) 843 (72.3%)
A 316 (28.2%) 323 (27.7%) 0.79 1.03 (0.85-1.23)
rs2978974* HWE: P=0.179
Co-dominant GG 254 (45.4%) 283 (48.5%)
Heterozygote GA 259 (46.3%) 256 (43.9%) 0.33 1.13 (0.89-1.44)
Homozygote AA 46 (8.2%) 44 (7.5%) 0.50 1.17 (0.75-1.82)
Dominant GG 254 (45.4%) 283 (48.5%)
GA+AA 305 (54.6%) 300 (51.5%) 0.29 1.13 (0.90-1.43)
Recessive GG+GA 513 (91.8%) 539 (92.5%)
AA 46 (8.2%) 44 (7.5%) 0.67 1.10 (0.71-1.69)
Overdominant GG+AA 300 (53.7%) 327 (56.1%)
GA 259 (46.3%) 256 (43.9%) 0.41 1.10 (0.87-1.39)
Allele G 767(68.6%) 822 (70.5%)
A 351(31.4%) 344 (29.0%) 0.33 1.09 (0.92-1.31)
OR: odds ratio; 95%CI: confidence interval.
* Cases of rs2978974 polymorphism missing n = 1
† Adjusted for age and body mass index.
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pancreatic cancers [9, 12-23, 26]. However, there is little 
insight into the relationship between PSCA and breast 
cancer.
Rs2294008 is located in exon 1 of PSCA and its C 
to T transition has been shown to reduce transcriptional 
activity of an upstream fragment of PSCA [28, 29]. 
Precious meta-analyses discovered that T allele of 
rs2294008 was a risk factor for cancer, particularly for 
gastric and bladder cancers [26, 27]. The T allele of 
rs2294008 increased risk for gastric cancer in Asian 
populations [30, 31] and the genetic variant rs2294008 
was identified to confer genetic susceptibility for bladder 
cancer risk in both Caucasian [12] and Asian [14, 20] 
populations. In this study, we found that the minor allele 
of rs2294008 was associated with a high risk of breast 
cancer among both premenopausal and postmenopausal 
women. There was no association between rs2294008 and 
ER status, although PR-positive tumors were associated 
with the T allele. In contrast, a study based on Korean 
women reported that the minor allele of rs2294008 
was associated with reduced breast cancer risk among 
premenopausal women, increased breast cancer risk 
among postmenopausal women, and that the T allele 
increased the ER-negative breast cancer risk [9]. Whist 
similar, our study provides a more robust analysis as it 
includes more patients as well as more detailed stratified 
analyses. Given the heterogeneous nature of breast cancer, 
the discrepancies between our findings and those of Kim 
et al. [9] may be explained by various factors, including 
region, lifestyle, genetic testing methods, and study 
design.
Rs2976392 is located in the intron 2 of PSCA 
and has a strong linkage disequilibrium with rs2294008 
C > T [24, 32]. The association of this SNP and cancer 
susceptibility has been widely investigated. Recent meta-
analysis has revealed the PSCA rs2976392 polymorphism 
was significantly associated with increased overall cancer 
risk [27]. Rs2978974 in the promoter region of PSCA 
showed low linkage disequilibrium with rs2294008 and the 
Ars2978974 allele was shown to contribute to bladder cancer 
susceptibility, presumably due to the loss of binding of 
ELK1 or other ETS proteins to the PSCA promoter [12]. 
A study based on 405 gallbladder cancer patients and 247 
healthy controls showed that the PSCA haplotype Trs2294008 
Ars2978974 conferred low risk of gallbladder cancer in males, 
while in females, the Trs2294008 Grs2978974 haplotype was related 
to increased gallbladder cancer risk [22]. Kim et al. found 
that there was no statistically significant relationship between 
rs2976392 and breast cancer risk, which is concordant with 
our study. However, we found the rs2976392 SNP was 
Table 2: Association between PSCA SNPs and age of breast cancer patients
Age(years) genotype 
distributions(case/control)
Co-dominant Dominant Recessive Allele































































A: Major allele; a: Minor allele; m= Heterozygote model; n= Homozygote model; OR: odds ratio; 95%CI: confidence 
interval.
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A: Major allele; a: Minor allele; m= Heterozygote model; n= Homozygote model; OR: odds ratio; 95%CI: confidence interval.
Table 4: The associations between the PSCA polymorphisms and clinical characteristics of breast cancer patients
Variables AA Aa aa Co-dominant Dominant Recessive Allele








<2 cm 98 75 15 1.00 (reference)










Negative 109 98 29 1.00 (reference)










Negative 124 110 13 1.00 (reference)











Variables AA Aa aa Co-dominant Dominant Recessive Allele







Negative 132 105 18 1.00 (reference)










Negative 190 166 33 1.00 (reference)











<2 cm 97 78 13 1.00 (reference)










Negative 120 105 11 1.00 (reference)










Negative 125 99 23 1.00 (reference)










Negative 129 104 22 1.00 (reference)










Negative 192 166 31 1.00 (reference)











<2 cm 89 87 12 1.00 (reference)










Negative 113 104 18 1.00 (reference)











associated with an increased risk of lymph node metastasis. 
This study provides the first investigation of associations 
between rs2978974 and breast cancer risk. We demonstrated 
that the minor allele of rs2978974 specifically increased the 
risk of breast cancer among postmenopausal women, while 
it was not associated with the risk of breast cancer among all 
patients, and was not associated with patient age or any of the 
clinicopathological features.
It is believed that haplotypes may be more important 
than any single SNP analysis in influencing a clinical 
response [33, 34]. To our knowledge, this is the first 
report of haplotypes in PSCA rs2294008, rs2976392, and 
rs2978974 polymorphisms. Haplotype analysis indicated 
that the Trs2294008 Ars2976392 Grs2978974 haplotype was associated 
with significantly increased risk of breast cancer.
This study has several limitations. First, the single-
center design may preclude extrapolation of our findings to 
other patient populations or ethnic groups. Second, we used 
a hospital-based case-control design, which may involve 
selection bias. Third, our sample size was relatively small, 
which may limit the strength of our stratified analyses. 
Fourth, we did not consider other important risk factors 
(e.g., high-dose radiation exposure at the chest, alcohol 
consumption, and other benign breast lesions), as we did not 
have access to these data. Therefore, a large well-designed 
prospective study is needed to validate our findings. 
Furthermore, biological function studies are crucial for 
elucidating the role of PSCA in breast cancer.
Our study revealed that the PSCA rs2294008 
polymorphism influenced the risk of breast cancer among 
Chinese women and the rs2978974 polymorphism 
may specifically increase the risk of breast cancer in 
postmenopausal women. We found that rs2294008 was 
associated with PR-positive status and rs2976392 was 
associated with lymph node metastasis among Chinese 
women with breast cancer. Furthermore, the Trs2294008 
Ars2976392 Grs2978974 haplotype may increase the susceptibility 
to breast cancer.
Variables AA Aa aa Co-dominant Dominant Recessive Allele







Negative 108 121 18 1.00 (reference)









Negative 117 122 16 1.00 (reference)










Negative 176 185 27 1.00 (reference)









A: Major allele; a: Minor allele; m= Heterozygote model; n= Homozygote model; OR: odds ratio; 95%CI: confidence interval; LN: 
lymph node; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor-2.
Table 5: The haplotype frequencies of PSCA polymorphisms and breast cancer risk
Haplotypes Controls (N=1166) 
n, %






C G G 526 (45.12%) 454(40.52%) 1.00 (reference)
C G A 317(27.17%) 315(28.12%) 1.15(0.94-1.41) 0.168
T A G 225(19.28%) 296(26.39%) 1.52 (1.23-1.89) <0.001
T A A 22 (1.90%) 25(2.26%) 1.32(0.73-2.37) 0.357




We included the cases with pathologically-
confirmed breast cancer, without history of any cancer, 
were treated at the Department of Oncology (Second 
Affiliated Hospital of Xi’an Jiaotong University) 
between January 2013 and October 2014. The healthy 
individuals who had visited the medical examination 
center at the Second Affiliated Hospital of Xi’an 
Jiaotong University for a check-up during the study 
period were included as controls. All individuals were 
Chinese Han women, and the controls were frequency-
matched to the cases according to age (±5 years) and 
menopausal status. Finally, 560 eligible patients with 
an average age 49.09 ± 11.02 years and 583 healthy 
age-matched controls were included in the study (Table 
6). The cases and controls exhibited similar clinical 
characteristics with the exception of body mass index 
(BMI) (P = 0.038).
A standardized epidemiological questionnaire was 
used to collect demographic and personal information. 
Clinical information was collected from medical 
records and pathological reports. All participants were 
informed regarding the study’s purpose and experimental 
procedures, and provided their written informed consent. 
The Human Research Committee at our institution 
approved the use of blood samples.
SNP selection and genotyping
Peripheral blood samples were collected in a 
standard tube and stored at –80°C. Genomic DNA was 
extracted from the peripheral whole blood samples using 
the Universal Genomic DNA Extraction Kit (version 
3.0; TaKaRa, Japan). To achieve a power of at least 
50%, only SNPs with a minor allele frequency of >0.01 
were included. Three primers were designed to amplify 
fragments of rs2294008, rs2978974, and rs2976392. 
Primers and PCR product sequences are shown in Table 
7. DNA concentrations were measured by spectrometry 
(DU530 UV/VIS spectrophotometer; Beckman Instruments, 
Fullerton, CA, USA), Sequenom MassARRAY RS1000 
was used for genotyping, and the related data were managed 
using Sequenom Typer 4.0 Software [35].
Table 6: The characteristics of breast cancer cases and cancer-free controls
Characteristics Cases Controls P
Number 560 583
Age (mean ± SD) 49.09±11.02 48.80±8.28 0.612
Menopausal status
 Premenopausal 264 281
 Postmenopausal 296 302 0.716
Procreative times
 <2 289 291 0.594
 ≥2 271 292
Body mass index (kg/m2)
 (mean ± SD) 22.52±2.84 22.95±3.21 0.038
Tumor size <2 cm 188
≥2 cm 372








LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor-2.
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Statistical analysis
Microsoft Excel and SPSS software (version 
21.0; SPSS Inc., Chicago, IL, USA) were used for all 
analyses. P-values were calculated using the χ2 test, 
and all tests were two-tailed; a P-value of <0.05 was 
considered statistically significant. The exact test was 
used to examine the distribution of each SNP among 
the controls, and their accordance with the Hardy-
Weinberg equilibrium. Five different genetic models 
were used to evaluate the risk of breast cancer, with 
“A” used to indicate the major allele and “a” used to 
indicate the minor allele: the allele model (a vs. A); the 
co-dominant model (homozygote model: aa vs. AA; 
heterozygote model: Aa vs. AA); the recessive model (aa 
vs. AA+Aa); the dominant model (AA vs. Aa+aa); and 
the over-dominant model (AA+aa vs. Aa). The allelic 
frequencies for each SNP were compared between cases 
and controls in each model using the χ2 test and SNPStats 
software [36, 37]. Power calculations were made by PS 
software (Power and Sample Size Calculation, which 
was downloaded online: http://biostat.mc.vanderbilt.
edu/wiki/Main/PowerSampleSize). Phase2.1 software 
was used to conduct all common haplotypes [34] and 
SPSS software was used to estimate the ORs and 95 % 
CIs for each haplotype. As shown in Table 6, there was a 
significant difference in BMI between breast cancer cases 
and controls (P = 0.038). BMI may be a confounder in 
the development of breast cancer. Therefore, to control 
for its effects, we used stratification analyses. First, we 
calculated OR1 and OR2 by stratification for BMI. Then, 
the ratio of the OR (unadjusted OR) and OR1/OR2 was 
calculated. If the ratio was close to 1, the results did 
not need to be adjusted, indicating that BMI was not a 
confounder. Otherwise, we would need to adjust results 
for BMI.
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